Program Management Team
This program involves the use of different platforms used for biomarker discovery and validation. Within Biomed, the following technology platforms are available: immunomics (cDNA phage display), proteomics, metabolomics and aptamer–based methods. These methods can be applied in different disease areas such as autoimmune diseases, neurological diseases and cardiovascular diseases (see domains immuno, cardio, neuro). A close collaboration exists between the biobank experts within Biomed, Ubilim and Clinical Research Centers of the Center for Medical Innovation (CMI) in Flanders in order to collect serum, plasma, cerebrospinal fluid, microvesicles, … according to standardized operating procedures. New biomarkers for different diseases will be evaluated for their diagnostic, prognostic and/or theranostic applicability, including nanomedicine approaches.
Furthermore, our expertise in biomarkers is used to broaden and strengthen the (inter)national contacts with clinical experts, clinical research centres, academic institutions but also life science companies.
Specific research focus
Apply immunomics, proteomics, metabolomics to identify new disease markers
Study the biological role of newly identified biomarkers for MS, Clinically Isolated Syndrome (CIS) and rheumatoid arthritis (RA)
Validate novel biomarkers for MS, CIS and RA
Develop biosensor platform for biomarkers for MS and RA
Identify and characterize antibody biomarkers that participate in post-spinal cord injury
Validate nanotechnology sensing platform for nanomedicine applications